Upadacitinib: Rinvoq

Marketing authorisation number 67257, date marketing authorisation granted: 20/01/2020

We publish synopses from Clinical Study Reports (CSR) to supplement the public information. This provides patients and healthcare providers with the results of our clinical trials and the evidence used to authorise Rinvoq.

Here you can find the CSR synopses after Rinvoq was granted marketing authorisation in Switzerland and the USA.

M13-542

Study Indication: Rheumatoide Arthritis
Phase: Phase 3
Study Name:
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects With Moderately to Severely Active Rheumatoide Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs)
EudraCT Number: 2015-003335-35

m13-542 CSR

M13-545

Study Indication: Rheumatoide Arthritis
Phase: Phase 3
Study Name:
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects With Moderately to Severely Active Rheumatoide Arthritis
EudraCT Number: 2015-003334-27

m13-545 CSR

M13-549

Study Indication: Rheumatoide Arthritis
Phase: Phase 3
Study Name:
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Moderately to Severely Active Rheumatoide Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs
EudraCT Number: 2015-003332-13

m13-549 CSR

M14-465

Study Indication: Rheumatoide Arthritis
Phase: Phase 3
Study Name:
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Moderately to Severely Active Rheumatoide Arthritis Who Are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)
EudraCT Number: 2015-003332-13

M14-465 CSR

M15-555

Study Indication: Rheumatoide Arthritis
Phase: Phase 3
Study Name:
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) in Subjects With Moderately to Severely Active Rheumatoide Arthritis With Inadequate Response to MTX
EudraCT Number: 2015-003376-75

M15-555 CSR
Popular Pages
External Links

Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.

Copyright © 2024 AbbVie Inc. North Chicago, Illinois, U.S.A.